MedTrace Logo

Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer

NCT00976365 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-06-09

No results posted yet for this study

Summary

The purpose of this study is to obtain evidence from test article with efficacy in Metastatic Breast Cancer patients. The average of all changes from baseline to post-treatment evaluations in global health/quality of life (QoL) subscale assessed by self-administered European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30).

Conditions

Interventions

DIETARY_SUPPLEMENT

THL-P

20ml/bottle, TID, 24weeks

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Taiwan THL Co.LTd.

    lead INDUSTRY

Principal Investigators

  • King-Jen Chang, M.D.,Ph.D. · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-01-31
Completion
2011-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976365 on ClinicalTrials.gov